EUVIMEDScopri EUVIMED
Systematische ÜbersichtOpen access · CC BY-NC-ND 4.0

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

Nisa Maria iD, Annisa Lazuardi Larasati iD, Indri Yuliani Hamdani iD, Jin-Gun Cho iD, Jan-Willem C Alffenaar iD

British Journal of Clinical Pharmacology · 2026-08 · 92 (8) · 2607-2623

DOI: 10.1002/bcp.70541 ↗

At a glance

Systematische Übersicht in British Journal of Clinical Pharmacology, published online on 2026-05-12. Written by Nisa Maria and 4 co-authors. Institution: School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia. Major MEDLINE topics: Diarylquinolines, Antitubercular Agents, Nitroimidazoles, Tuberculosis, Multidrug-Resistant. 54 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Australia Awards.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by combining safety data from clinical trials, implementation and pharmacovigilance studies. We conducted a search using PubMed, Medline and Web of Science to identify studies that reported AE data for bedaquiline–pretomanid‐based regimens. In total, 14 studies from various countries were included in the analysis, comprising seven clinical trials, six implementation studies and one pharmacovigilance study. AE detection methods differed between clinical trials and implementation studies. Clinical trials utilised structured and standardised detection methods, whereas implementation and pharmacovigilance studies relied on spontaneous reporting with a higher prevalence of AEs reported in clinical trials (62.2–100%) compared to implementation studies (41.8–72.8%). Serious AEs developed in 2.2–30.2% of patients. Among those with serious AEs, 7.7–54.3% required interruption of TB drugs, while 3.5–13% required withdrawal of TB drugs. AE outcomes showed full recovery in 79.2%. However, 23–32% of patients reported AEs even after completing their treatment. Understanding AEs is crucial for healthcare professionals to enhance patient care, as early detection and appropriate management of AEs is essential in TB treatment to increase tolerability, minimise complications and optimise clinical outcomes. Further research is necessary to implement active monitoring for this new TB regimen in real‐world settings.

Subjects

MeSH terms (MEDLINE)

DiarylquinolinesAntitubercular AgentsNitroimidazolesTuberculosis, Multidrug-ResistantHumansPharmacovigilanceClinical Trials as TopicDrug Therapy, Combination

Author keywords

adverse eventsbedaquilinedrug‐resistant tuberculosispretomanid

Substances

DiarylquinolinesbedaquilineAntitubercular AgentsNitroimidazolespretomanid

Authors and institutions

  • School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Faculty of Pharmacy, Universitas Indonesia, Depok, Indonesia.
  • Sydney Infectious Diseases Institute, University of Sydney, Sydney, Australia.
  • Westmead Hospital, Sydney, Australia.
  • Departement of Pharmacy, Universitas Indonesia Hospital, Jawa Barat, Indonesia.
  • Department of Respiratory and Sleep Medicine, Westmead Hospital, Sydney, Australia.

ORCID profiles: Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin-Gun Cho, Jan-Willem C Alffenaar

Funding

  • Australia Awards

Cite

APA

Maria, N., Larasati, A. L., Hamdani, I. Y., Cho, J. G., & Alffenaar, J. C. (2026). Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies. British Journal of Clinical Pharmacology, 92(8), 2607-2623. https://doi.org/10.1002/bcp.70541

Vancouver

Maria N, Larasati AL, Hamdani IY, Cho JG, Alffenaar JC. Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies. British Journal of Clinical Pharmacology. 2026;92(8):2607-2623. doi:10.1002/bcp.70541

BibTeX
@article{Maria2026,
  author = {Maria, Nisa and Larasati, Annisa Lazuardi and Hamdani, Indri Yuliani and Cho, Jin-Gun and Alffenaar, Jan-Willem C},
  title = {Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  volume = {92},
  number = {8},
  pages = {2607--2623},
  doi = {10.1002/bcp.70541}
}
Start for free →